The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

OBJECTIVES: To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA). METHODS: This double-blind study included adult patients with moderate-to-severe activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan, Wang, Liangwei, Alevizos, Ilias, Gunsior, Michele, Falloon, Judith, Illei, Gabor, St Clair, E William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407378/
https://www.ncbi.nlm.nih.gov/pubmed/37541743
http://dx.doi.org/10.1136/rmdopen-2023-003317